Loading...
The importance of detecting and treating depression early in patients with neurological disorders is supported by increasing evidence. Estimates of the prevalence of depression range from 20% to 72% after stroke, 40% to 50% in Parkinson disease, 19% to 54% in multiple sclerosis, and up to 55% in epilepsy. The adverse effects of depression on patients' quality of life, duration of hospital stay, engagement in treatment, and outcome are well recognized.
To determine whether antidepressants are more effective than placebo for the treatment of depression in neurological disorders, and whether any such benefit is associated with improved function overall, researchers conducted a literature review and meta-analysis. They formally reviewed 20 rando…